• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heliyon . Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID

tetano

Editor, Senior Moderator
Heliyon


. 2021 Jan 9;7(1):e05951.
doi: 10.1016/j.heliyon.2021.e05951. eCollection 2021 Jan.
Understanding the implications of SARS-CoV-2 re-infections on immune response milieu, laboratory tests and control measures against COVID-19


Jelili Olaide Mustapha[SUP] 1 [/SUP], Idris Nasir Abdullahi[SUP] 2 [/SUP], Odunayo O R Ajagbe[SUP] 3 [/SUP], Anthony Uchenna Emeribe[SUP] 4 [/SUP], Samuel Ayobami Fasogbon[SUP] 5 [/SUP], Solomon Oloche Onoja[SUP] 6 [/SUP], Charles Egede Ugwu[SUP] 7 [/SUP], Chikodi Modesta Umeozuru[SUP] 8 [/SUP], Folake Olubunmi Ajayi[SUP] 8 [/SUP], Wudi Natasha Tanko[SUP] 8 [/SUP], Pius Omoruyi Omosigho[SUP] 9 [/SUP], Abdulmumuni Samuel Aliyu[SUP] 10 [/SUP], Halima Ali Shuwa[SUP] 11 [/SUP], Justin Onyebuchi Nwofe[SUP] 7 [/SUP], Amos Dangana[SUP] 12 [/SUP], Ovye Alaba[SUP] 12 [/SUP], Peter Elisha Ghamba[SUP] 13 [/SUP], Yakubu Ibrahim[SUP] 2 [/SUP], Dorcas Aliyu[SUP] 4 [/SUP], Olawale Sunday Animasaun[SUP] 8 [/SUP], Nkechi Blessing Ugboaja[SUP] 14 [/SUP], Mala Alhaji Baba Mallam[SUP] 15 [/SUP], Sharafudeen Dahiru Abubakar[SUP] 2 [/SUP], Maijidda Saidu Aminu[SUP] 15 [/SUP], Hadiza Yahaya[SUP] 15 [/SUP], Silifat Oyewusi[SUP] 15 [/SUP]



Affiliations

Abstract

Several months after the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), cases of re-infection after recovery were reported. The extent and duration of protective immunity after SARS-CoV-2 infection is not fully understood. As such, the possibility of re-infection with SARS-CoV-2. Furthermore, cases of re-infection were mainly due to different variants or mutant SARS-CoV-2. Following the fast and pandemic-scale spread of COVID-19, mutations in SARS-CoV-2 have raised new diagnostic challenges which include the redesign of the oligonucleotide sequences used in RT-PCR assays to avoid potential primer-sample mismatches, and decrease sensitivities. Since the initial wave of the pandemic, some regions had experienced fresh outbreaks, predisposing people to be susceptible to SARS-CoV-2 re-infection. Hence, this article sought to offer detailed biology of SARS-CoV-2 re-infections and their implications on immune response milieu, diagnostic laboratory tests and control measures against COVID-19.

Keywords: COVID-19; Diagnostic challenges; Immune evasion; Infection control; SARS-CoV-2 re-infection.
 
Back
Top Bottom